Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249

PubMed  Google Scholar 

Zhang S, Sun K, Zheng R, et al. Cancer incidence and mortality in China, 2015. J Natl Cancer Center. 2021;1(1):2–11

CAS  Google Scholar 

Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450–1462

CAS  PubMed  Google Scholar 

Shen KY, Zhu Y, Xie SZ, et al. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives. J Hematol Oncol. 2024;17(1):25

PubMed  PubMed Central  Google Scholar 

EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236

Google Scholar 

Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;394(10204):1145–1158

PubMed  PubMed Central  Google Scholar 

Moris D, Palta M, Kim C, et al. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin. 2023;73(2):198–222

PubMed  Google Scholar 

Tang Y, Wang L, Teng F, et al. The clinical characteristics and prognostic factors of combined hepatocellular carcinoma and cholangiocarcinoma, hepatocellular carcinoma and intrahepatic cholangiocarcinoma after surgical resection: a propensity score matching analysis. Int J Med Sci. 2021;18(1):187–198

CAS  PubMed  PubMed Central  Google Scholar 

Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. J Clin Oncol. 2020;38(36):4317–4345

CAS  PubMed  Google Scholar 

Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248(1):84–96

PubMed  Google Scholar 

Spolverato G, Bagante F, Tsilimigras D, et al. Management and outcomes among patients with mixed hepatocholangiocellular carcinoma: a population-based analysis. J Surg Oncol. 2019;119(3):278–287

CAS  PubMed  Google Scholar 

Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604

PubMed  PubMed Central  Google Scholar 

Forner A, Vidili G, Rengo M, et al. Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int. 2019;39(Suppl 1):98–107

PubMed  Google Scholar 

Yao KJ, Jabbour S, Parekh N, et al. Increasing mortality in the United States from cholangiocarcinoma: an analysis of the National Center for Health Statistics Database. BMC Gastroenterol. 2016;16(1):117

PubMed  PubMed Central  Google Scholar 

Zhao Q, Yu WL, Lu XY, et al. Combined hepatocellular and cholangiocarcinoma originating from the same clone: a pathomolecular evidence-based study. Chin J Cancer. 2016;35(1):82

PubMed  PubMed Central  Google Scholar 

Feng M, Pan Y, Kong R, et al. Therapy of primary liver cancer. Innovation (Cambridge). 2020;1(2): 100032

CAS  Google Scholar 

Saez-Ibañez AR, Upadhaya S, Partridge T, et al. Landscape of cancer cell therapies: trends and real-world data. Nat Rev Drug Discov. 2022;21(9):631–632

PubMed  Google Scholar 

Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62–68

CAS  PubMed  PubMed Central  Google Scholar 

Bach PB, Giralt SA, Saltz LB. FDA approval of tisagenlecleucel: promise and complexities of a $475 000 cancer drug. JAMA. 2017;318(19):1861–1862

PubMed  Google Scholar 

Baulu E, Gardet C, Chuvin N, et al. TCR-engineered T cell therapy in solid tumors: state of the art and perspectives. Sci Adv. 2023;9(7):eadf3700

CAS  PubMed  PubMed Central  Google Scholar 

Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319(25):1676–1680

CAS  PubMed  Google Scholar 

Xu MY, Zeng N, Liu CQ, et al. Enhanced cellular therapy: revolutionizing adoptive cellular therapy. Exp Hematol Oncol. 2024;13(1):47

CAS  PubMed  PubMed Central  Google Scholar 

Wang LL, Janes ME, Kumbhojkar N, et al. Cell therapies in the clinic. Bioeng Transl Med. 2021;6(2): e10214

PubMed  PubMed Central  Google Scholar 

Guedan S, Ruella M, June CH. Emerging cellular therapies for cancer. Annu Rev Immunol. 2019;37:145–171

CAS  PubMed  Google Scholar 

Wu D, Li Y. Application of adoptive cell therapy in hepatocellular carcinoma. Immunology. 2023;170(4):453–469

CAS  PubMed  Google Scholar 

Hao Y, Stuart T, Kowalski MH, et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat Biotechnol. 2024;42(2):293–304

CAS  PubMed  Google Scholar 

Borcherding N, Bormann NL, Kraus G. scRepertoire: an R-based toolkit for single-cell immune receptor analysis. F1000Res. 2020;9:47

CAS  PubMed  PubMed Central  Google Scholar 

Tirosh I, Izar B, Prakadan SM, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016;352(6282):189–196

CAS  PubMed  PubMed Central  Google Scholar 

Li X, Guo X, Zhu Y, et al. Single-cell transcriptomic analysis reveals BCMA CAR-T cell dynamics in a patient with refractory primary plasma cell Leukemia. Mol Ther. 2021;29(2):645–657

CAS  PubMed  Google Scholar 

Morotti M, Albukhari A, Alsaadi A, et al. Promises and challenges of adoptive T-cell therapies for solid tumours. Br J Cancer. 2021;124(11):1759–1776

PubMed  PubMed Central  Google Scholar 

Li Y, Zheng Y, Liu T, et al. The potential and promise for clinical application of adoptive T cell therapy in cancer. J Transl Med. 2024;22(1):413

CAS  PubMed  PubMed Central  Google Scholar 

Andrea AE, Chiron A, Mallah S, et al. Advances in CAR-T cell genetic engineering strategies to overcome hurdles in solid tumors treatment. Front Immunol. 2022;13: 830292

CAS  PubMed  PubMed Central  Google Scholar 

Lo W, Parkhurst M, Robbins PF, et al. Immunologic recognition of a shared p53 mutated neoantigen in a patient with metastatic colorectal cancer. Cancer Immunol Res. 2019;7(4):534–543

CAS  PubMed  PubMed Central  Google Scholar 

Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114(8):1537–1544

CAS  PubMed  PubMed Central  Google Scholar 

Kirtane K, Elmariah H, Chung CH, et al. Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead. J Immunother Cancer. 2021;9(7):1

Google Scholar 

Heine A, Juranek S, Brossart P. Clinical and immunological effects of mRNA vaccines in malignant diseases. Mol Cancer. 2021;20(1):52

CAS  PubMed  PubMed Central  Google Scholar 

Huang Q, Wu X, Wang Z, et al. The primordial differentiation of tumor-specific memory CD8(+) T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes. Cell. 2022;185(22):4049-4066.e4025

CAS  PubMed  Google Scholar 

Yin E, Sun N, He J. Tumor-draining lymph node-derived tumor-specific memory CD8(+) T cells: a key player in PD-1/PD-L1 immunotherapy. Signal Transduct Target Ther. 2023;8(1):111

CAS  PubMed  PubMed Central  Google Scholar 

O’Melia MJ, Lund AW, Thomas SN. The biophysics of lymphatic transport: engineering tools and immunological consequences. iScience. 2019;22:28–43

PubMed  PubMed Central